Connect with execs from Axios, The New York Times, Paramount and more.
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
To manage 300,000 creators, Unilever automates everything but the relationship
Unilever is using AI to vet creators and automate workflows as it scales a 300,000-creator network without handing over creative decisions.
Nike versus Adidas: Who’s spending more in race to claim the World Cup crown?
With the World Cup at the midway point, ad spend estimates show the apparel rivals taking opposite tacks in their media approaches.
Platforms’ AI dilemma: scale without sameness
Using AI to create content risks a lot of it looking the same. But the platforms agree creativity will always come from humans.